AU2018215785B2 - Materials and methods for delivering nucleic acids to cochlear and vestibular cells - Google Patents

Materials and methods for delivering nucleic acids to cochlear and vestibular cells Download PDF

Info

Publication number
AU2018215785B2
AU2018215785B2 AU2018215785A AU2018215785A AU2018215785B2 AU 2018215785 B2 AU2018215785 B2 AU 2018215785B2 AU 2018215785 A AU2018215785 A AU 2018215785A AU 2018215785 A AU2018215785 A AU 2018215785A AU 2018215785 B2 AU2018215785 B2 AU 2018215785B2
Authority
AU
Australia
Prior art keywords
harmonin
mice
promoter
anc80
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018215785A
Other languages
English (en)
Other versions
AU2018215785A9 (en
AU2018215785A1 (en
Inventor
Yukako ASAI
Gwenaelle GELEOC
Jeffrey Holt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Original Assignee
Boston Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital filed Critical Boston Children's Hospital
Publication of AU2018215785A1 publication Critical patent/AU2018215785A1/en
Publication of AU2018215785A9 publication Critical patent/AU2018215785A9/en
Priority to AU2023214288A priority Critical patent/AU2023214288A1/en
Application granted granted Critical
Publication of AU2018215785B2 publication Critical patent/AU2018215785B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018215785A 2017-02-06 2018-02-06 Materials and methods for delivering nucleic acids to cochlear and vestibular cells Active AU2018215785B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023214288A AU2023214288A1 (en) 2017-02-06 2023-08-09 Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455197P 2017-02-06 2017-02-06
US62/455,197 2017-02-06
PCT/US2018/017104 WO2018145111A1 (en) 2017-02-06 2018-02-06 Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023214288A Division AU2023214288A1 (en) 2017-02-06 2023-08-09 Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Publications (3)

Publication Number Publication Date
AU2018215785A1 AU2018215785A1 (en) 2019-08-22
AU2018215785A9 AU2018215785A9 (en) 2019-09-26
AU2018215785B2 true AU2018215785B2 (en) 2023-08-31

Family

ID=63040112

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018215785A Active AU2018215785B2 (en) 2017-02-06 2018-02-06 Materials and methods for delivering nucleic acids to cochlear and vestibular cells
AU2023214288A Pending AU2023214288A1 (en) 2017-02-06 2023-08-09 Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023214288A Pending AU2023214288A1 (en) 2017-02-06 2023-08-09 Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Country Status (7)

Country Link
US (2) US11730827B2 (enExample)
EP (1) EP3576696A4 (enExample)
JP (2) JP2020508648A (enExample)
CN (1) CN111698975A (enExample)
AU (2) AU2018215785B2 (enExample)
CA (1) CA3052704A1 (enExample)
WO (1) WO2018145111A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039375A1 (en) 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
DE102018103924A1 (de) * 2018-02-21 2019-08-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Gentherapeutische Behandlung von Schwerhörigkeit
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
JP7430652B2 (ja) 2018-03-05 2024-02-13 ザ チルドレンズ メディカル センター コーポレーション 蝸牛および前庭細胞に核酸を送達するための組成物および方法
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN112703016B (zh) 2018-04-27 2024-11-22 分贝治疗公司 肌球蛋白15启动子及其用途
US12491223B2 (en) 2018-09-27 2025-12-09 Akouos, Inc. Method for treating an auditory neuropathy spectrum disorder
US12534739B2 (en) 2018-10-11 2026-01-27 Decibel Therapeutics, Inc. AAV1 vectors and uses thereof for treatment of otic indications
CN113825521A (zh) * 2018-12-21 2021-12-21 美利坚合众国由健康及人类服务部部长代表 腺相关病毒及其用于内耳疗法的用途
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
WO2020163761A1 (en) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
EP3959324B1 (en) * 2019-04-26 2025-09-17 President and Fellows of Harvard College Aav vectors encoding mini-pcdh15 and uses thereof
CN114269926A (zh) 2019-04-26 2022-04-01 美商圣加莫治疗股份有限公司 Aav工程化
US12667628B2 (en) 2019-07-03 2026-06-30 Children's Medical Center Corporation Compositions and methods for gene replacement
EP4007814A1 (en) 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
TWI896570B (zh) 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
EP4055175A4 (en) * 2019-11-04 2023-11-29 Decibel Therapeutics, Inc. Cochlear inner hair cell promoters and uses thereof
CN119391775A (zh) * 2019-11-04 2025-02-07 分贝治疗公司 前庭支持细胞启动子和其用途
WO2021150850A1 (en) * 2020-01-24 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Svcs. Adeno-associated viruses and their uses for inner ear therapy
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2022129543A1 (en) * 2020-12-18 2022-06-23 Institut Pasteur Gene therapy for treating usher syndrome
CN114762733B (zh) * 2021-01-15 2025-03-18 中国科学院脑科学与智能技术卓越创新中心 耳蜗外毛细胞特异性顺式调节元件及其应用
KR102751019B1 (ko) * 2021-03-03 2025-01-09 연세대학교 산학협력단 Kcnq4 유전자 교정용 가이드 rna 및 이를 포함하는 난청 치료용 조성물
WO2023147383A1 (en) 2022-01-25 2023-08-03 Bridgebio Services Inc. Gene therapy for genetic hearing loss
CN116606885A (zh) * 2023-02-21 2023-08-18 东南大学 一种Lhfpl5基因敲除鼠构建实验方法
WO2024239226A1 (zh) * 2023-05-23 2024-11-28 苏州星奥拓维生物技术有限公司 耳蜗毛细胞特异性启动子及其用途
CN119061007A (zh) * 2023-06-02 2024-12-03 苏州星奥拓维生物技术有限公司 耳蜗支持细胞基因治疗和再生的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673634B2 (en) * 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
WO2011075838A1 (en) 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
KR100990160B1 (ko) * 2010-03-15 2010-10-29 도태환 기전력 안정화 영구자석 발전기
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
CA3007476A1 (en) * 2015-12-11 2017-06-15 Massachusetts Eye And Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
WO2017136764A1 (en) 2016-02-05 2017-08-10 The General Hospital Corporation Hybrid system for efficient gene delivery to cells of the inner ear
US20190254997A1 (en) * 2016-07-21 2019-08-22 The Regents Of The University Of California Methods for inducing stereocilia on hair cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Géléoc, G.G.S., et al., "Gene Therapy Restores Auditory and Vestibular Function in a Mouse Model of Usher Syndrome, Type I", Inner Ear Biology, 2016, abstract S7 *

Also Published As

Publication number Publication date
CN111698975A (zh) 2020-09-22
AU2018215785A9 (en) 2019-09-26
EP3576696A4 (en) 2020-09-16
US11730827B2 (en) 2023-08-22
JP2023036921A (ja) 2023-03-14
CA3052704A1 (en) 2018-08-09
AU2023214288A1 (en) 2023-11-30
AU2018215785A1 (en) 2019-08-22
EP3576696A1 (en) 2019-12-11
US20190351072A1 (en) 2019-11-21
JP2020508648A (ja) 2020-03-26
JP7601916B2 (ja) 2024-12-17
WO2018145111A9 (en) 2019-08-29
WO2018145111A1 (en) 2018-08-09
US20230330268A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US20230330268A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
US12102692B2 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
US12281313B2 (en) Compositions and methods for delivering nucleic acids to cochlear and vestibular cells
CN111683688A (zh) 听力损失的基因疗法治疗
WO2026043797A1 (en) Methods and compositions for prevention and treatment of hearing loss
HK40095383A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK40074395A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK1262434B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK40003977B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
WO2025166351A1 (en) Compositions and methods for hearing loss
HK40003977A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)